Back to search

Article

Plasma concentrations of nirmatrelvir and molnupiravir required for inhibition of SARS-CoV-2 replication differ between rhesus macaques and humans

2025-10-01

Abstract excerpt

Early during the COVID-19 pandemic, non-human primate (NHP) infection models emerged as highly useful tools for preclinical screening of antiviral drugs. However, it is uncertain whether NHP models can be used to precisely inform optimal dosing in humans. We previously established and validated mathematical models which were fit to SARS-CoV-2 viral loads from human clinical trials. These models identified that pla...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bb380abe-2041-5a58-9f76-5cd6ed4394b3
DOI
10.1101/2025.09.25.678525
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Plasma concentrations of nirmatrelvir and molnupiravir required for inhibition of SARS-CoV-2 replication differ between rhesus macaques and humansDOI 10.1101/2025.09.25.678525
A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity
Mathematical modeling explains differential SARS CoV-2 kinetics in lung and nasal passages in remdesivir treated rhesus macaquesSemantic proximity
Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus MacaquesSemantic proximity
Host Factors Modulate Nirmatrelvir–Ritonavir Efficacy in COVID-19 Patients: A Viral Dynamics Modeling StudySemantic proximity
Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studySemantic proximity
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected miceSemantic proximity
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2.Semantic proximity
Molnupiravir clinical trial simulation suggests that polymerase chain reaction underestimates antiviral potency against SARS-CoV-2Semantic proximity
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2Semantic proximity
The Antiviral Mechanism of Action of Molnupiravir in Humans with COVID-19Semantic proximity
Viral dynamic modeling of SARS-CoV-2 in non-human primatesSemantic proximity
Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium <i>in vitro</i>Semantic proximity
Select a neighboring publication to make it the new centre.